Andes-virus-induced cytokine storm is partially suppressed by ribavirin

Antiviral Therapy

Volumn 18, Issue 4, 2013, Pages 575-584

  Khaiboullina, Svetlana F ^a   Rizvanov, Albert A ^b   Lombardi, Vincent C ^a   Morzunov, Sergey P ^a   Reis, Helton J ^c   Palotás, András ^d   Jeor, Stephen St ^e  

^a UNIVERSITY OF NEVADA   (United States)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d Asklepios Med   (Hungary)

^e UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; RANTES; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ANDES VIRUS; ARTICLE; BIOACCUMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE STORM; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; VIRUS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CHEMOKINE CCL5; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HANTAVIRUS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; NF-KAPPA B; RIBAVIRIN; TUMOR NECROSIS FACTOR-ALPHA; VERO CELLS; VIRAL LOAD;

EID: 84885337497     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2524     Document Type: Article

References (49)

1. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4- triazole-3-carboxamide. Science 1972; 177:705-706.
2. Hruska JF, Bernstein JM, Douglas RG, Jr., Hall CB. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother 1980; 17:770-775.
3. Povey RC. In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus. Am J Vet Res 1978; 39:175-178.
4. Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother 1989; 33:2009-2011.
5. de la Torre JC, Alarcon B, Martinez-Salas E, Carrasco L, Domingo E. Ribavirin cures cells of a persistent infection with foot-and-mouth disease virus in vitro. J Virol 1987; 61:233-235.
6. Durr FE, Lindh HF. Efficacy of ribavirin against influenza virus in tissue culture and in mice. Ann N Y Acad Sci 1975; 255:366-371.
7. Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 1984; 149:420-427.
8. Oxford JS. Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). J Gen Virol 1975; 28:409-414.
9. Sidwell RW, Huffman JH, Barnett BB, Pifat DY. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother 1988; 32:331-336.
10. Wahren B, Oberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology 1980; 14:7-15.
11. Bean B. Antiviral therapy: current concepts and practices. Clin Microbiol Rev 1992; 5:146-182.
12. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:1375-1379.
13. Goswami BB, Borek E, Sharma OK, Fujitaki J, Smith RA. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun 1979; 89:830-836.
14. Streeter DG, Witkowski JT, Khare GP, et al. Mechanism of action of 1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A 1973; 70:1174-1178.
15. Stridh S. Determination of ribonucleoside triphosphate pools in influenza A virus-infected MDCK cells. Arch Virol 1983; 77:223-229.
16. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30:115-133.
17. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77:481-488.
18. Meier V, Burger E, Mihm S, Saile B, Ramadori G. Ribavirin inhibits DNA, RNA, and protein synthesis in PHAstimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection. J Med Virol 2003; 69:50-58.
19. Martín J, Navas S, Quiroga JA, Pardo M, Carreno V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 10:635-644.
20. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119-1127.
21. Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 2011; 1:590-598.
22. Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol 2007; 3:218-225.
23. Jiang Z, Kunimoto M, Patel JA. Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. J Virol 1998; 72:2496-2499.
24. Krakauer T, LeDuc JW, Krakauer H. Serum levels of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome. Viral Immunol 1995; 8:75-79.
25. Mori M, Rothman AL, Kurane I, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis 1999; 179:295-302.
26. Temonen M, Mustonen J, Helin H, Pasternack A, Vaheri A, Holthofer H. Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: an immunohistochemical study. Clin Immunol Immunopathol 1996; 78:47-55.
27. Vapalahti O, Lundkvist A, Vaheri A. Human immune response, host genetics, and severity of disease. Curr Top Microbiol Immunol 2001; 256:153-169.
28. Kanerva M, Mustonen J, Vaheri A. Pathogenesis of puumala and other hantavirus infections. Rev Med Virol 1998; 8:67-86.
29. Zaki SR, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146:552-579.
30. Singer CA, Baker KJ, McCaffrey A, AuCoin DP, Dechert MA, Gerthoffer WT. p38 MAPK and NF-kB mediate COX-2 expression in human airway myocytes. Am J Physiol Lung Cell Mol Physiol 2003; 285:L1087-L1098.
31. Khaiboullina SF, Rizvanov AA, Deyde VM, St Jeor SC. Andes virus stimulates interferon-inducible MxA protein expression in endothelial cells. J Med Virol 2005; 75:267-275.
32. Khaiboullina SF, Rizvanov AA, Otteson E, Miyazato A, Maciejewski J, St Jeor S. Regulation of cellular gene expression in endothelial cells by Sin Nombre and prospect hill viruses. Viral Immunol 2004; 17:234-251.
33. Henninger DD, Panes J, Eppihimer M, et al. Cytokineinduced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 1997; 158:1825-1832.
34. Rothlein R, Czajkowski M, O'Neill MM, Marlin SD, Mainolfi E, Merluzzi VJ. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by proinflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. J Immunol 1988; 141:1665-1669.
35. Linderholm M, Ahlm C, Settergren B, Waage A, Tarnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-a, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J Infect Dis 1996; 173:38-43.
36. Khaiboullina SF, Netski DM, Krumpe P, St Jeor SC. Effects of tumor necrosis factor alpha on Sin Nombre virus infection in vitro. J Virol 2000; 74:11966-11971.
37. Kim HK, Park HR, Sul KH, Chung HY, Chung J. Induction of RANTES and CCR5 through NF-kB activation via MAPK pathway in aged rat gingival tissues. Biotechnol Lett 2006; 28:17-23.
38. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar WL. Co-operative functions between nuclear factors NFkB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004; 61:354-370.
39. Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993; 177:1809-1814.
40. Wiedermann CJ, Kowald E, Reinisch N, et al. Monocyte haptotaxis induced by the RANTES chemokine. Curr Biol 1993; 3:735-739.
41. Xu LL, Warren MK, Rose WL, Gong W, Wang JM. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol 1996; 60:365-371.
42. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antivir Ther 1999; 4:211-219.
43. Loppnow H, Libby P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol 1989; 122:493-503.
44. Hutchins D, Steel CM. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 1994; 58:80-84.
45. Ramadori G, Christ B. Cytokines and the hepatic acutephase response. Semin Liver Dis 1999; 19:141-155.
46. Legrand-Poels S, Schoonbroodt S, Piette J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J 2000; 349:765-773.
47. Klingström J, Plyusnin A, Vaheri A, Lundkvist A. Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. J Virol 2002; 76:444-449.
48. Bonville CA, Easton AJ, Rosenberg HF, Domachowske JB. Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J Virol 2003; 77:1237-1244.
49. Bonville CA, Lau VK, DeLeon JM, et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J Virol 2004; 78:7984-7989.